LAUSR

Simple Summary Non-melanoma skin cancer is the most common cancer in humans and has been linked to skin infections with betaHPV. This has led to the development of vaccine candidates against these viruses. This review provides an overview of the currently followed prophylactic and therapeutic vaccination strategies. Abstract Non-melanoma skin cancer (NMSC) is the most common cancer in humans with increasing incidence. Meanwhile, a growing body of evidence has provided a link between skin infections with HPV of the genus beta (betaHPV) and the development of cutaneous squamous cell carcinomas (cSCCs). Based on this association, the development of vaccines against betaHPV has become an important research topic. This review summarizes the current advances in prophylactic and therapeutic betaHPV vaccines, including progresses made in preclinical testing and clinical trials.